Skip to content

Evaluation of auriculotherapy associated with standard treatment in diabetic patients

Evaluation of the auriculotherapy effectiveness associated with standard treatment for patients with Diabetes Mellitus type II: Pragmatic, randomized, double-blind, multicenter clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-10br88dj
Enrollment
Unknown
Registered
2021-11-08
Start date
2021-12-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive episodes

Interventions

The intervention will be carried out by professionals trained and trained to apply the protocols. Standard treatment (tp): includes orientation, medication in use and change of habits. 200 participant
(2) left PA associated with tp (AEtp)
(3) alternating the laterality of the PA associated with the tp (AAtp), starting with the right and ending with the left. In these groups, roasted mustard seeds will be used, fixed with microporous ta
E02.190.044.133

Sponsors

Universidade Federal de Santa Catarina
Lead Sponsor
Universidade Federal do Ceará
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 18 years or older diagnosed with Type 2 Diabetes Mellitus

Exclusion criteria

Exclusion criteria: Body mass index greater than 30, amputees and on dialysis

Design outcomes

Primary

MeasureTime frame
Glucose verification, through the evaluation of capillary blood glucose with the use of strips that make electrical capture of the hemoglobin drop (Glycated Hemoglobin), before, at the end of the intervention and after two months.;Evaluation of the quality of life of volunteers, using the SF-36 questionnaire, before, at the end of treatment and after two months of the last treatment.

Secondary

MeasureTime frame
Evaluate the amount of plasma intracellular adhesion molecule through specific kits, before, at the end of treatment and after two months of the last treatment;Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI-BR). The PSQI-BR assesses sleep quality over the last month. The evaluation will be carried out before, at the end of treatment and after two months of the last treatment.;Assessment of mood disorders through the reduced version of the Depression, Anxiety and Stress Scale (DASS-21). The evaluation will be carried out before, at the end of treatment and after two months of the last treatment.;To assess the mobility and functional balance of individuals with T2D, the Timed Up and Go (TUG) test will be used. This test quantifies functional mobility in seconds through the time the individual performs the task of getting up from a chair. The evaluation will be carried out before, at the end of treatment and after two months of the last treatment.;Evaluation of pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha), using specific kits. The evaluation will be carried out before, at the end of treatment and after two months of the last treatment.;Assessment of adherence to standard treatment using a questionnaire to identify how the individual is using the medication periodically. The evaluation will be carried out before, at the end of treatment and after two months of the last treatment.

Countries

Brazil

Contacts

Public ContactMorgana da Silva
morgana.silva@ufsc.br+55(48)999560610

Outcome results

None listed

Source: REBEC (via WHO ICTRP)